Initial Glasgow Coma Scale score predicts outcome following thrombolysis for posterior circulation stroke.

BACKGROUND Randomized trials of thrombolytic stroke treatment have either excluded patients with posterior circulation ischemia or used inclusion criteria making enrollment of these patients less likely. Consequently, there is less published information on thrombolytic therapy for posterior circulation stroke. OBJECTIVE To determine effective thrombolytic treatment times for posterior circulation stroke and factors that might help predict clinical outcome. DESIGN We describe our experience treating 21 consecutive patients with either intravenous or intra-arterial thrombolytic therapy for posterior circulation ischemic stroke between October 9, 1993, and February 19, 2001. MAIN OUTCOME MEASURES National Institutes of Health Stroke Scale, Glasgow Coma Scale, and modified Rankin Scale scores were evaluated at baseline, and the modified Rankin Scale was measured 3 months after stroke, with a good outcome being a modified Rankin Scale score of 2 or less. RESULTS Nine patients received intravenous therapy; 12 patients received intra-arterial therapy. The median National Institutes of Health Stroke Scale score at onset was 20 (range, 2-39), and the median Glasgow Coma Scale score was 9 (range, 3-15). Twelve patients were treated within 8 hours of symptom onset (range, 1 1/2 hours to 16 days). Nine patients (43%) had a modified Rankin Scale score of 2 or less at 3 months. The initial Glasgow Coma Scale score and treatment within 8 hours of symptom onset were each associated with good outcome, but the initial National Institutes of Health Stroke Scale score was not predictive. CONCLUSIONS Thrombolytic therapy for posterior circulation stroke may be beneficial even when initiated 8 hours after symptom onset. Level of consciousness, as measured by Glasgow Coma Scale score, seems to be a more important predictor of outcome than the initial National Institutes of Health Stroke Scale score.

[1]  L. Pazdera,et al.  Outcome at 30 days in the New England Medical Center Posterior Circulation Registry. , 2002, Archives of neurology.

[2]  M. Hommel,et al.  Thrombolytic therapy with streptokinase in acute ischemic stroke. , 1996, The New England journal of medicine.

[3]  S. Felber,et al.  Long-Term Outcome after Local Intra-Arterial Fibrinolysis of Basilar Artery Thrombosis , 2000, Cerebrovascular Diseases.

[4]  G. Schroth,et al.  Local intra-arterial thrombolysis in acute ischemic stroke. , 1998, Stroke.

[5]  M. Kaste,et al.  The European Cooperative Acute Stroke Study (ECASS) , 1993 .

[6]  M. Pessin,et al.  Basilar artery occlusive disease in the New England Medical Center Posterior Circulation Registry. , 2004, Archives of neurology.

[7]  G. Donnan,et al.  Thrombolysis in the Vertebrobasilar Circulation: The Australian Urokinase Stroke Trial , 1997 .

[8]  W. Hacke,et al.  Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. , 1996, Stroke.

[9]  Multicentre Acute Stroke Trial—Italy Group Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke , 1995, The Lancet.

[10]  Gregory,et al.  Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. , 1988, Stroke.

[11]  G. Hankey,et al.  Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. , 1996, Journal of the American Medical Association (JAMA).

[12]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[13]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[14]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[15]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[16]  M. Diringer,et al.  Relationship between clot location and outcome after basilar artery thrombolysis. , 1997, AJNR. American journal of neuroradiology.

[17]  C. Derdeyn,et al.  Collateral circulation and outcome after basilar artery thrombolysis. , 1998, AJNR. American journal of neuroradiology.

[18]  W. Heiss,et al.  Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke. , 1998, Archives of neurology.

[19]  G. Schlaug,et al.  Diffusion-weighted imaging and National Institutes of Health Stroke Scale in the acute phase of posterior-circulation stroke. , 2001, Archives of neurology.

[20]  W. Hacke,et al.  Acute vertebral-basilar thrombosis. Angiologic-clinical comparison and therapeutic implications. , 1986, Acta radiologica. Supplementum.

[21]  P. Adeleine,et al.  Intravenous r-TPA in vertebrobasilar acute infarcts , 2004, Neurology.

[22]  E. Dooley National Institute of Neurological Disorders and Stroke , 2006 .

[23]  L. Munari,et al.  RANDOMIZED CONTROLLED TRIAL OF STREPTOKINASE, ASPIRIN, AND COMBINATION OF BOTH IN TREATMENT OF ACUTE ISCHEMIC STROKE , 1995 .

[24]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[25]  A R Localio,et al.  Reliability and validity of estimating the NIH stroke scale score from medical records. , 1999, Stroke.

[26]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[27]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.